1 Rochester Regional Health, Rochester, NY, 2 Rochester Regional Health and 3Uni-versity of Rochester School of Medicine & Dentistry, Rochester, NY. RATIONALE: Penicillin skin testing (PST) may be unnecessary to delabel low-risk patients. We describe the utility and safety of a penicillin allergy history algorithm (PAHA) that incorporates graded challenges to penicillin (GCP) into the inpatient management of penicillin allergy. METHODS: Pharmacists identified adult inpatients with penicillin allergy receiving alternative antibiotics when a b-lactam antibiotic was indicated. The PAHA was administered to identify patients for PST versus GCP. Patients were evaluated by an allergist in person or via telemedicine. Patients with negative evaluations were transitioned to b-lactam therapy. RESULTS: Out of 106 patients qualifying for inclusion, 50 consented. Per the PAHA, 23 and 27 patients underwent PST and GCP, respectively. PST group historical reactions included recent hives (12, 52.2%), angioedema (11, 47.8%), dyspnea (7, 30.4%), syncope (3, 13.0%), and/or other (2, 8.7%). GCP group historical reactions included hives (11, 40.7%), nonspecific rash (15, 55.6%), and unknown (1, 3.7%). PST was negative in 23/ 23 patients. GCP was negative in 26/27 (96.3%) patients, with one patient experiencing flushing and eye swelling, treated with diphenhydramine. Patients transitioned from vancomycin (11/50, 22%), fluoroquinolones (7/ 50, 14%), aztreonam (3/50, 6%), and/or linezolid (2/50, 4%) to a b-lactam antibiotic. 11/50 (22%) patients were transitioned from an intravenous cephalosporin to amoxicillin. 628 days of second-line antibiotic therapy were avoided, with an estimated direct cost savings of $371/patient. CONCLUSIONS: The use of the PAHA incorporating GCP is safe, effective, and facilitated inpatient transition to b-lactam antibiotics. Our approach adds to the growing evidence of the safety of GCP in appropriate patients.
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A 5-Year Retrospective Review of Graded Drug Challenges Performed in an Outpatient Allergy Practice There is limited data on the characteristics and safety of graded drug challenges (GDC). This study characterizes GDCs performed at an outpatient allergy practice over a five-year period. METHODS: Patients of five allergy/immunology physicians who underwent a GDC from 2013-2018 were identified through an electronic medical record report. GDCs to penicillin-related antibiotics that were preceded by a penicillin skin testing were excluded. Patient demographics, historical reactions, purpose, and outcome of the GDC were recorded. RESULTS: 172 GDCs were performed, of which 159 (92.4%) were negative, and 13 (7.6%) were positive. There were 67 (39%) males and 105 (61%) females, with an average age of 38.16 28.3 years. The time since the reported ADR was 8.0 6 13.0 years. GDCs were performed for 113 (65.7%) antibiotics, 37 (21.5%) NSAIDs, 7 (4 %) oral steroids and 15 (8.7%) other medications. The most commonly challenged antibiotics were amoxicillin (31.0%), macrolides (18.6%), cephalosporins (16.8%), and sulfamethoxazole (15.9%). Although the majority of GDCs were performed electively (51.2%), other common indications included management of recurrent infections (18.6%) and analgesia (11.0%). There was no statistically significant difference between the positive and negative challenges with respect to gender, age, time since reaction, number of drug allergies, drug challenged, or historical reaction. Of the 13 positive challenges, 10 were to antibiotics and 3 were to NSAIDs. One of 13 (7.7%) positive challenges, performed to azithromycin, required epinephrine for flushing, dyspnea, and wheezing. CONCLUSIONS: GDCs can be safely performed in the outpatient setting and are an effective strategy for de-labeling drug allergies. 
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